Chemokine receptor-4 targeted PET/CT imaging with 68Ga-Pentixafor in head and neck cancer—a comparison with 18F-FDG and CXCR4 immunohistochemistry
| dc.contributor.author | Hadebe, Bawinile | |
| dc.contributor.author | Harry, Lerwine | |
| dc.contributor.author | Gabela, Lerato | |
| dc.contributor.author | Masikane, Siphelele | |
| dc.contributor.author | Patel, Maryam | |
| dc.contributor.author | Zwane, Sizwe | |
| dc.contributor.author | Pillay, Venesen | |
| dc.contributor.author | Bipath, Presha | |
| dc.contributor.author | Cebekhulu, Nonhlanhla | |
| dc.contributor.author | Nyakale, Nozipho E. | |
| dc.contributor.author | Ramdass, Prathima | |
| dc.contributor.author | Msimang, Mpumelelo | |
| dc.contributor.author | Aldous, Colleen | |
| dc.contributor.author | Sathekge, Mike Machaba | |
| dc.contributor.author | Vorster, Mariza | |
| dc.date.accessioned | 2024-12-13T06:44:16Z | |
| dc.date.available | 2024-12-13T06:44:16Z | |
| dc.date.issued | 2024-06 | |
| dc.description | DATA AVAILABITY STATEMENT: The raw data supporting the conclusions of this article will be made available by the authors on request. | en_US |
| dc.description.abstract | Please read abstract in article. | en_US |
| dc.description.department | Nuclear Medicine | en_US |
| dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
| dc.description.sdg | SDG-09: Industry, innovation and infrastructure | en_US |
| dc.description.sponsorship | The Nuclear Medicine Research Infrastructure (NuMeRi), the Discovery Foundation, and PentixaPharm AG, Berlin, Germany. | en_US |
| dc.description.uri | https://www.mdpi.com/journal/diagnostics | en_US |
| dc.identifier.citation | Hadebe, B.; Harry, L.; Gabela, L.; Masikane, S.; Patel, M.; Zwane, S.; Pillay, V.; Bipath, P.; Cebekhulu, N.; Nyakale, N.; et al. Chemokine Receptor-4 Targeted PET/CT Imaging with 68Ga-Pentixafor in Head and Neck Cancer—A Comparison with 18F-FDG and CXCR4 Immunohistochemistry. Diagnostics 2024, 14, 1375. https://doi.org/10.3390/diagnostics14131375. | en_US |
| dc.identifier.issn | 2075-4418 (online) | |
| dc.identifier.other | 10.3390/diagnostics14131375 | |
| dc.identifier.uri | http://hdl.handle.net/2263/100007 | |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.rights | © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | en_US |
| dc.subject | Pentixafor | en_US |
| dc.subject | SDG-03: Good health and well-being | en_US |
| dc.subject | SDG-09: Industry, innovation and infrastructure | en_US |
| dc.subject | Head and neck squamous cell carcinoma (HNSCC) | en_US |
| dc.subject | Positron emission tomography/computed tomography (PET/CT) | en_US |
| dc.subject | Human immunodeficiency virus (HIV) | en_US |
| dc.subject | Chemokine receptor 4 (CXCR4) | en_US |
| dc.title | Chemokine receptor-4 targeted PET/CT imaging with 68Ga-Pentixafor in head and neck cancer—a comparison with 18F-FDG and CXCR4 immunohistochemistry | en_US |
| dc.type | Article | en_US |